NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
No Longer AvailableN/A
Sponsor: Pfizer
Conditions: Multiple Myeloma
Interventions: Elranatamab
Provide pre-approval single-patient Expanded Access (Compassionate Use) of elranatamab for patients with relapsed/refractory multiple myeloma
Eligibility overview
Sex: ALL
Age: 18 Years to —
Study type: EXPANDED_ACCESS
Eligibility criteria
Must have relapsed/refractory multiple myeloma (RRMM) and be refractory to at least one immunomodulatory drug, one proteasome inhibitor and one anti-CD38 antibody. Must have evidence of disease progression after last therapy. Must have exhausted all available treatment options accessible as local standard of care and not be eligible for participation in any ongoing clinical trial. Additional eligibility criteria may be required.